“科技每年都会见证一些神奇的真理和制造出令人眼花缭乱的东西,如吴雨霏穆利斯《创新的聚合酶链式反应》。 不幸的是，他们中的大多数被淘汰出局。而聚合酶链式反应则预示着基因组的革命.
这是一项关于思维的挑战，这项任务要求挑战者来概述制药行业需要采取哪些创新，来适应这优胜劣汰的游戏规则。挑战者不需要发表明确的解决方案，你只需要清楚的描述已经存在的，可能会成为下一个制药趋势的大事。这将有助于制药行业寻找明天的药物，生产新药。
What Disruptive Innovations Does Pharma Need To Discover Tomorrow’s Drugs?
AWARD: $5,000 USD | DEADLINE: 10/15/12 | ACTIVE SOLVERS: 220 | POSTED: 9/14/12 Source: InnoCentive Challenge ID: 9932826 Type: Ideation
Detailed Description & Requirements
Background
Productivity in drug discovery & development – the number of new drugs reaching patients – has been declining. At the same time, R&D spending has been increasing. Industry experts calculate the mean R&D spend per new drug on the market is $4-11 billion dollars.
2012 Forbes Article: The Truly Staggering Cost of Inventing New Drugs
The Problem
Various factors contribute to this high development cost. The most prominent is the high rate of attrition (failure) on drug like compounds as they pass through the drug development process. For every 10,000 compounds that appear interesting during basic research, 1 may reach market as an approved drug.
Causes of compounds not progressing include:
Lack of efficacy or potency
Unfavorable pharmacology/pharmacodynamics
Toxicity or safety
Increasing regulatory stringency in approving drugs for clinical trial and for market
Increasing emphasis on stratification of patient populations for administration of drugs (personalized medicine)
Factors contributing to these causes include, but are not limited to:
Assay systems and platforms that poorly replicate drug effects in humans
Lack of new therapeutic drug targets being identified e.g. phenotypic screening data is difficult to convert into new molecular targets
Animal experimental data, too, poorly predicts effects in humans / translational medicine
Lack of good validated biomarkers to measure disease states or predict
[更多]
